why choose us

First received: June 08, 2023

Clinical Trial: Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Clinical Stage III Cutaneous Melanoma AJCC v8

Study Type: INTERVENTIONAL


Official Title: The Safety and Efficacy of Endostar Combined With Toripalimab as Postoperative Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma: A Prospective, Single-arm, Open-la

Brief Summary: The goal of this clinical trial is to evaluate the efficacy and safety of Endostar combined with Toripalimab in the adjuvant treatment of resectable stage III-oligometastatic stage IV melanoma, and to find effective biomarkers of efficacy based on tumor paraffin tissue specimens and peripheral blood.The main questions it aims to answer are:The efficacy and safety of the combination treatment regimen;Finding suitable biomarkers can refine the patients with effective treatmentAfter a series of evaluation, if the…

Read more